Sci Adv
. 2024 Jul 26;10(30):eadn5405.
doi: 10.1126/sciadv.adn5405. Epub 2024 Jul 26. https://pubmed.ncbi.nlm.nih.gov/39058789/
Fetal hypoplastic lungs have multilineage inflammation that is reversed by amniotic fluid stem cell extracellular vesicle treatment
Lina Antounians 1 2, Rebeca Lopes Figueira 1 2, Bharti Kukreja 3, Michael L Litvack 4, Elke Zani-Ruttenstock 1 2, Kasra Khalaj 1 2, Louise Montalva 1 2, Fabian Doktor 1 2, Mikal Obed 1 2, Matisse Blundell 1 2, Taiyi Wu 3, Cadia Chan 5 6, Richard Wagner 7, Martin Lacher 7, Michael D Wilson 5 6, Martin Post 4 8, Brian T Kalish 3 6 9, Augusto Zani 1 2 10
Affiliations Expand
- PMID: 39058789
- PMCID: PMC11277482
- DOI: 10.1126/sciadv.adn5405
Abstract
Antenatal administration of extracellular vesicles from amniotic fluid stem cells (AFSC-EVs) reverses features of pulmonary hypoplasia in models of congenital diaphragmatic hernia (CDH). However, it remains unknown which lung cellular compartments and biological pathways are affected by AFSC-EV therapy. Herein, we conducted single-nucleus RNA sequencing (snRNA-seq) on rat fetal CDH lungs treated with vehicle or AFSC-EVs. We identified that intra-amniotically injected AFSC-EVs reach the fetal lung in rats with CDH, where they promote lung branching morphogenesis and epithelial cell differentiation. Moreover, snRNA-seq revealed that rat fetal CDH lungs have a multilineage inflammatory signature with macrophage enrichment, which is reversed by AFSC-EV treatment. Macrophage enrichment in CDH fetal rat lungs was confirmed by immunofluorescence, flow cytometry, and inhibition studies with GW2580. Moreover, we validated macrophage enrichment in human fetal CDH lung autopsy samples. Together, this study advances knowledge on the pathogenesis of pulmonary hypoplasia and further evidence on the value of an EV-based therapy for CDH fetuses.
